Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To examine the characteristics of people with HIV (PWH) who prefer remaining on daily oral antiretroviral therapy (ART), rather than switching to long-acting ART (LA-ART). DESIGN: Building upon a discrete choice experiment (DCE), we examined characteristics of individuals who always selected their current daily oral tablet regimen over either of two hypothetical LA-ART options presented in a series of 17 choice tasks. METHODS: We used LASSO to select sociodemographic, HIV-related, and other health-related predictors of preferring current therapy over LA-ART, and logistic regression to measure the associations with those characteristics. RESULTS: Among 700 PWH in Washington State and Atlanta, Georgia, 11% of participants ( n = 74) chose their current daily treatment over LA-ART in all DCE choice tasks. We found that people with lower educational attainment, good adherence, more aversion to injections, and who participated from Atlanta to be more likely to prefer their current daily regimen over LA-ART. CONCLUSIONS: Gaps in ART uptake and adherence remain, and emerging LA-ART treatments show promise to address these challenges and help a larger portion of PWH to achieve viral suppression, but preferences for these new treatments are understudied. Our results show that certain drawbacks of LA-ART may help to maintain demand for daily oral tablets, especially for PWH with certain characteristics. Some of these characteristics (lower educational attainment and Atlanta participation) were also associated with a lack of viral suppression. Future research should focus on overcoming barriers that impact preferences for LA-ART among those patients who could benefit most from this innovation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV
- Date Crossref
- 07/06/2023
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Washington and Economics (CHOICE) Institute pays non établi dans la noticeUniversité ou école supérieure
-
Oregon Health & Science University pays non établi dans la noticeUniversité ou école supérieure
-
Pfizer (United States) pays non établi dans la noticeEntreprise
-
Emory University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
National Institute of Allergy and Infectious Diseases pays non établi dans la noticeStructure de recherche
-
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com) pays non établi dans la noticeInstitution
-
School of Medicine Division of Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Inc Pfizer pays non établi dans la noticeEntreprise
-
Rollins School of Public Health Department of Global Health pays non établi dans la noticeUniversité ou école supérieure
-
Department of Global Health pays non établi dans la noticeInstitution
-
Department of Psychology pays non établi dans la noticeInstitution
-
Division of Allergy & Infectious Diseases pays non établi dans la noticeInstitution
and Economics (CHOICE) Institute — University of Washington, Oregon Health & Science University et Pfizer (United States), avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.